Stock performance snapshot and what stands out now

Erasca (ERAS) has attracted fresh attention after a sharp 1 day decline of about 9.8%, following a roughly 6.8% fall over the past week, even as the stock remains up strongly year to date.

For context, Erasca has recorded a gain of about 9.8% over the past month, but is down roughly 22.6% over the past 3 months, which highlights how volatile the stock has been for investors tracking shorter time frames.

Taking a step back, Erasca’s recent pullback comes after a very strong run, with a year to date share price return above 200% and a 1 year total shareholder return that is a multiple of that level. As a result, momentum now looks more mixed as investors reassess the balance between potential growth and risk.

If you are weighing Erasca against other healthcare stocks with artificial intelligence exposure, it could be helpful to scan a focused list of 39 healthcare AI stocks

With Erasca posting a very large 1-year total return and a year-to-date gain above 200%, while analyst targets sit well above the last close, is this an undervalued opportunity or a stock already pricing in future growth?

Preferred price to book of 9.5x: Is it justified?

Erasca trades on a P/B ratio of 9.5x while peers in the US Biotechs industry sit at 2.5x on average, which points to a much richer valuation at the recent $11.97 share price.

P/B compares the market value of a company to the book value of its net assets, and it is often used for businesses that are not yet profitable. In this case, investors are paying a multiple of the company’s accounting equity that is well above both direct peers and the broader biotech group.

For Erasca, this premium multiple is sitting against a backdrop of no meaningful revenue reported yet, ongoing net losses of $277.02m, and forecasts that the company will remain unprofitable over the next 3 years. Revenue is forecast to grow rapidly, and the stock’s strong 1 year and year to date returns suggest investors are already paying up for that potential rather than current earnings.

Compared with the US Biotechs industry average P/B of 2.5x and a peer group average of 6.3x, Erasca’s 9.5x places it firmly at the expensive end of the spectrum. The market is valuing each dollar of book equity at a level that is materially higher than what is typical across the sector, which is important context for anyone weighing the recent share price moves.

Result: Price-to-book of 9.5x (OVERVALUED)

However, the story could change quickly if clinical trial data disappoints or funding conditions tighten, given the company’s ongoing net losses and reliance on future progress.

Next Steps

With sentiment clearly mixed, you do not need to wait for consensus. Check the data yourself, weigh both the upside and the concerns, and review the 1 key reward and 4 important warning signs.

Looking for more investment ideas?

Do not stop with a single stock story. Broaden your watchlist now so you can spot opportunities early instead of hearing about them after the big moves.

• Target potential mispricings by scanning a curated set of 49 high quality undervalued stocks that combine quality fundamentals with appealing valuations.
• Strengthen your income focus by zeroing in on 9 dividend fortresses that aim to pair higher yields with sturdier business profiles.
• Tilt toward resilience by checking 64 resilient stocks with low risk scores that screen for stocks with lower risk scores and more defensive characteristics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.